Mainboard · BSE and NSEDraft filed

Encube Ethicals Limited IPO: dates, price band, lot size, objects of the issue

Get updates on this IPO

Dates, price band, allotment and listing notices by email, and new views from SEBI-registered research analysts on InsightPier by email.

Dates, allotment, listing and analyst views. Stop anytime.

By continuing you agree to the Terms and Privacy policy

Updated Sun 15 Nov 2026, 8:04 pm IST · Source: DRHP dated Sat 1 Aug 2026

Key facts

Price band
Not announced
Lot size
Not announced
Lot amount at the upper band
Not announced
Issue size at the upper band
₹3,000.00 crore
Fresh issue
None
DRHP dated Sat 1 Aug 2026, page 1
Offer for sale
₹3,000.00 crore
DRHP dated Sat 1 Aug 2026, page 1
Bid dates
Not announced
Listing date
Not announced
Risk factors
83
DRHP dated Sat 1 Aug 2026, page 85
Proposed exchanges
BSE and NSE

Timeline (IST)

  1. Draft filedThu 6 Aug 2026 confirmedDRHP dated Sat 1 Aug 2026
  2. OpensDates to be announced
  3. ClosesDates to be announced
  4. AllotmentDates to be announced
  5. Refund and unblockDates to be announced
  6. ListingDates to be announced

Company and promoters

As described in the DRHP

We are a global pharmaceutical formulations platform with deep domain expertise in technically complex topical and transdermal dosage forms, serving 50 countries including regulated markets such as the United States, UK and Europe, and India as of March 31, 2026.

DRHP dated Sat 1 Aug 2026, page 229

Promoters

  • 1 individual promoter

DRHP dated Sat 1 Aug 2026, page 300

Shareholding

HoldingBefore the issueAfter the issue
Promoters and promoter group80.91%Not stated in the DRHP
Public19.09%Not stated in the DRHP

DRHP dated Sat 1 Aug 2026, page 119

Financials (restated)

ItemFinancial Year ended March 31, 2026Financial Year ended March 31, 2025Financial Year ended March 31, 2024
Revenue from operations₹1,848.70 crore₹1,344.80 crore₹1,085.90 crore
Profit after tax₹436.70 crore₹249.60 crore₹156.10 crore
Net worth₹1,915.20 crore₹1,495.20 crore₹1,243.40 crore
Total borrowingsNot stated in the draftNot stated in the draftNot stated in the draft

DRHP dated Sat 1 Aug 2026, page 90

Who is selling in the offer for sale

Selling shareholderTypeShares offeredAmount at the upper band
Individual shareholderIndividualNot announcedNot announced
Frontier Investment Holdings Pte. Ltd.CompanyNot announcedNot announced
Total offer for sale₹3,000.00 crore

DRHP dated Sat 1 Aug 2026, page 1

Peer comparison (as in the DRHP)

Name of the companyStandalone / consolidatedTotal revenue from operations (₹ in million)Face value (₹ per equity share)Closing price of each equity share as on July 31, 2026P/E ratio (x)EPS Basic (₹ per equity share)EPS Diluted (₹ per equity share)RoNW (%)Net asset value per share (₹)
Our CompanyConsolidated18,4871[●]^[●]^14.3814.3625.21%64.29
Dr. Reddy’s Laboratories LimitedConsolidated3,37,00211,147.6022.7950.4150.3511.75%453.98
Lupin LimitedConsolidated2,79,58022,413.9520.73116.75116.4426.90%489.98
Zydus Lifesciences LimitedConsolidated2,71,48411,126.5022.4950.0950.0919.74%269.43
Aurobindo Pharma LimitedConsolidated3,36,53111,579.3526.1760.3460.349.94%652.39
Glenmark Pharmaceuticals LimitedConsolidated1,69,82512,233.3046.3048.2648.2414.07%372.33
Alembic Pharmaceuticals LimitedConsolidated73,4492797.0523.2234.3334.3312.42%288.70
Rubicon Research LimitedConsolidated17,54011,492.6097.4915.5215.3126.97%77.10
Gland Pharma LimitedConsolidated64,30712,504.440.2162.3562.2810.53%625.62
OneSource Specialty Pharma LimitedConsolidated14,21611,621.75NA(6.44)(6.44)(1.26)%508.22

Reproduced from the DRHP dated Sat 1 Aug 2026, page 134; InsightPier adds no figures

Risk factors

83 total
  1. Most revenue comes from the Global Generics and Global CDMO businesses; a slowdown in either could hurt results (DRHP page 26)
  2. Most products are made for markets outside India, mainly the United States and Europe, exposing the company to foreign-market risks (DRHP page 28)
  3. Manufacturing sites face regulator and customer inspections; a quality failure could bring regulatory action or lost contracts (DRHP page 29)
  4. Product quality concerns could lead customers and distributors to cancel orders or end agreements (DRHP page 31)
  5. Shares bought in the offer cannot be sold on an exchange immediately; listing could be delayed (DRHP page 85)

All 83 risk factors, DRHP pages 26 to 85

Offer document

Research

Research reports on IPOs from SEBI-registered research analysts, published on InsightPier.

Research reports on IPOs from SEBI-registered research analysts